National Center for Advancing Translational Sciences (93.350)
National Center for Advancing Translational Sciences (Assistance Listing 93.350) is run by the National Institutes of Health, part of the Department of Health and Human Services. It awarded $3.1 billion in 867 grants from fiscal 2021 to 2025, about $3.6 million per award on average. 34 funding opportunities are open or forecast now.
The typical award was $728,667. Half of the 867 awards fell between $200,000 and $2.3 million, and they ranged from $1,000 to $59.2 million.
- Awarded, FY 2021 to 2025$3.1 billion
- Grant awards867
- Typical award$728,667
- Awarded in FY 2025$599 million
- Size rank122 of 1,823
- Type of assistanceCooperative agreements
Key findings
- Annual funding fell from $671 million in fiscal 2021 to $599 million in fiscal 2025.
- It is the 122nd largest of 1,823 federal grant programs by five-year awards.
- The 20 largest recipients received 45% of the money.
- Awards went to recipients in 41 states and territories.
What the program funds
NCATS' mission is to turn research observations into health solutions through translational science. We work to develop or enhance the development, testing, and implementation of diagnostics and therapeutics for a wide range of diseases and conditions. Key approaches include understanding what’s similar across diseases to spur multiple treatments at a time, developing models that better predict a person’s reaction to treatment, enhancing clinical trials so results more accurately reflect the patient population, and leveraging real-world data and data science approaches to address public health needs. Facilitating these approaches are our robust partnerships with other government agencies, including other NIH institutes, centers, and offices; industry; academia; nonprofit organizations; and patients, patient advocates, and other communities. NCATS' vision is to bring more treatments for all people more quickly.
Open and forecast opportunities
- Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)
- NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
- NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
- Limited Competition: NCATS Clinical and Translational Science Award (CTSA) Program Research Education Grants Programs (R25 - Clinical Trial Not Allowed)
- Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- Successor-in-Interest (Type 6 Parent Clinical Trial Optional)
- NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)
- Clinical and Translational Science Award (UM1 Clinical Trial Optional)
- Limited Competition: Mentored Research Career Development Program Award in Clinical and Translational Science Awards (CTSA) Program (K12 Clinical Trial Optional)
- Limited Competition: Ruth L. Kirschstein National Research Service Award (NRSA) Predoctoral Research Training Grant for the Clinical and Translational Science Awards (CTSA) Program (T32 Clinical Trial Not Allowed)
- Limited Competition: Ruth L. Kirschstein National Research Service Award (NRSA) Postdoctoral Research Training Grant for the Clinical and Translational Science Awards (CTSA) Program (T32 Clinical Trial Not Allowed)
- Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)
- Pilot Projects Investigating Understudied Proteins Associated with Rare Diseases (R03 Clinical Trial Not Allowed)
- NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed)
- NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- Expanding the Target Landscape by Drugging the Undruggable (R21 Clinical Trial Not Allowed)
- INCLUDE Project: Transformative Research Awards for Down syndrome (R01 Clinical Trial Not Allowed)
- INCLUDE Project: Clinical Trials Phased Awards for Down syndrome Research (R61/R33 Clinical Trial Required)
- Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
- SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional)
- NIH Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough Award (Parent [R44] Clinical Trial Optional)
- NIH Collaborative International Research Project (Parent PF5 Clinical Trial Optional)
- Limited Competition: Small Grant Program for the NCATS Clinical and Translational Science Award (CTSA) Program (Clinical Trial Optional)
Rules from the program listing
Who can apply
See above.
What the money can and cannot pay for
NCATS is all about getting more treatments to all patients more quickly. There are more than 10,000 known rare diseases and only a few hundred have safe, effective treatments. A novel drug, device or intervention can take 14 years and $2 billion to develop, with a failure rate exceeding 95%. NCATS is directly addressing this problem by discovering new technologies and other approaches that could greatly accelerate the process of developing and deploying solutions that can be used by all translational researchers. The Clinical and Translational Science Award (CTSA) Program supports a national, collaborative consortium focused on bringing more treatments to all people more quickly through advancing clinical and translational science. The Trial Innovation Network, inclusive of Trial Innovation Centers and a Recruitment Innovation Center, are intended to serve as a national model for innovation in clinical trial management and operations, participant recruitment, and will facilitate the implementation of multi-site clinical studies by the CTSA network. The CTSA Collaborative and Innovation Acceleration Awards supports synergistic activities that accelerate the translational research process through collaboration and innovation. NCATS supports a network of research consortia, each targeted to several related rare diseases. NCATS also supports an extensive resource of information for the public on rare diseases.
Matching requirements
This program has no statutory formula. Matching requirements are not applicable to this assistance listing. MOE requirements are not applicable to this assistance listing.
Award range and average, in the agency's words
NCATS Assistance: $1 - $11,215,948, average: $1,718,935
Funding history and past recipients
From fiscal 2021 to 2025, National Center for Advancing Translational Sciences (93.350) awarded $3.1 billion across 867 grant awards, an average of $3.6 million per award.
Who usually wins
Colleges and universities received 82% of the money, nonprofits 8.6% and small businesses 3.9%.
| Recipient type | Awards | Amount | Share |
|---|---|---|---|
| Colleges and universities | 523 | $2.5 billion | 82% |
| Nonprofits | 157 | $267 million | 8.6% |
| Other | 34 | $171 million | 5.5% |
| Small businesses | 152 | $119 million | 3.9% |
| Businesses | 1 | $1.7 million | less than 0.1% |
By state
35 states have a page for this program: those that received at least $1 million or 10 awards.
| State | Awards | Amount |
|---|---|---|
| California | 107 | $405 million |
| New York | 73 | $351 million |
| Massachusetts | 69 | $239 million |
| North Carolina | 56 | $208 million |
| Pennsylvania | 49 | $200 million |
| Texas | 52 | $167 million |
| Ohio | 43 | $126 million |
| Illinois | 28 | $119 million |
| Tennessee | 13 | $98.0 million |
| Minnesota | 17 | $92.7 million |
| Washington | 20 | $81.5 million |
| Maryland | 37 | $76.1 million |
| Wisconsin | 16 | $75.9 million |
| Michigan | 23 | $75.0 million |
| Connecticut | 7 | $67.2 million |
| Missouri | 8 | $64.9 million |
| Georgia | 10 | $64.4 million |
| Colorado | 27 | $58.7 million |
| Alabama | 14 | $56.1 million |
| Florida | 24 | $56.0 million |
| Oregon | 13 | $55.9 million |
| Indiana | 15 | $40.5 million |
| Virginia | 24 | $40.4 million |
| Utah | 13 | $38.2 million |
| New Jersey | 13 | $31.6 million |
| South Carolina | 9 | $29.4 million |
| District of Columbia | 13 | $26.4 million |
| Kansas | 5 | $25.7 million |
| Iowa | 9 | $25.1 million |
| Arkansas | 6 | $24.8 million |
| New Mexico | 5 | $23.7 million |
| Kentucky | 6 | $23.7 million |
| New Hampshire | 2 | $8.4 million |
| Arizona | 4 | $5.0 million |
| Montana | 2 | $756,860 |
| Delaware | 2 | $583,370 |
| Louisiana | 2 | $299,226 |
| Rhode Island | 24 | $284,168 |
| Nebraska | 1 | $35,886 |
| North Dakota | 1 | $31,138 |
| Mississippi | 1 | $6,000 |